flexim
novel
type
flexibl
nucleosid
garner
attent
due
unpreced
activ
human
coronavirus
exhibit
highli
promis
level
activ
filovirus
flexnucleosid
potent
recombin
ebola
viru
cell
ec
lm
mcguigan
prodrug
activ
sudan
virusinfect
hela
cell
ec
lm
elsevi
ltd
right
reserv
sinc
first
report
fatal
outbreak
mid
member
filovirida
viru
famili
includ
ebola
viru
ebov
sudan
viru
sudv
marburg
viru
marv
continu
devast
mani
area
across
globe
mortal
rate
high
one
worst
outbreak
ebov
occur
west
africa
document
infect
claim
live
includ
nearli
health
care
worker
filovirus
group
envelop
singlestrand
negativesens
rna
virus
caus
fatigu
vomit
sever
hemorrhag
fever
member
filovirida
famili
zoonot
virus
primari
reservoir
specul
fruit
bat
howev
unclear
reservoir
transmiss
human
occur
filovirus
highli
contagi
easili
spread
interact
infect
individu
direct
contact
bodili
fluid
includ
vomit
sweat
saliva
respiratori
secret
high
potenti
reemerg
lethal
virus
particularli
due
superspread
imper
viabl
treatment
option
identifi
order
better
fight
crippl
pathogen
next
outbreak
occur
date
avail
fda
approv
treatment
filoviru
infect
variou
therapeut
option
pursu
includ
vaccin
monoclon
antibodi
recombin
protein
mani
yet
reach
clinic
trial
may
ultim
translat
well
effect
treatment
made
readili
avail
outbreak
particularli
suboptim
condit
one
therapeut
option
develop
antivir
treatment
use
nucleosid
analogu
nucleosid
analogu
long
cornerston
antivir
therapi
due
abil
inhibit
viral
replic
mimic
structur
natur
nucleosid
recogn
cellular
viral
enzym
includ
viral
dna
rna
polymeras
moreov
contain
variou
structur
modif
lead
cessat
viral
replic
typic
due
chain
termin
variou
nucleosid
analogu
filovirus
ebov
alreadi
propos
includ
sadenosylhomocystein
hydrolas
sahas
inhibitor
fig
monophosph
deriv
adenosin
analogu
act
nonoblig
chain
termin
howev
none
progress
clinic
recent
monophosphoramid
prodrug
adenosin
analogu
target
ebov
rnadepend
rna
polymeras
rdrp
exhibit
potent
activ
ebov
marv
demonstr
potenti
find
effect
nucleosid
inhibitor
filovirus
past
sever
year
research
laboratori
focus
develop
flexibl
nucleosid
analogu
term
flexim
one
type
flexim
featur
purin
ring
split
imidazol
pyrimidin
moieti
two
piec
remain
connect
singl
cac
bond
thu
introduc
free
rotat
two
heterocycl
compon
without
lose
necessari
group
need
recognit
fig
strateg
design
retain
hydrogen
bond
pattern
need
recognit
allow
flexnucleosid
interact
altern
bind
moieti
differ
amino
acid
bind
pocket
previous
unattain
parent
nucleosid
studi
within
lab
also
shown
inher
flexibl
allow
increas
bind
affin
compar
correspond
rigid
inhibitor
well
abil
overcom
point
mutat
biolog
relev
enzymat
bind
site
thu
provid
potenti
overcom
develop
drug
resist
importantli
recent
work
flexim
version
fdaapprov
nucleosid
acyclovir
reveal
signific
activ
human
coronavirus
middl
east
respiratori
syndrom
merscov
sever
acut
respiratori
syndrom
sarscov
repres
first
nucleosid
analogu
exhibit
low
micromolar
level
anticov
activ
groundbreak
sinc
nucleosid
analogu
point
fail
show
viabl
level
activ
deadli
virus
result
prompt
evalu
flexanalogu
virus
particularli
given
dual
anticov
antiebov
activ
recent
note
herein
report
antifiloviru
activ
analogu
well
correspond
phosphoramid
prodrug
fig
synthesi
target
compound
began
substitut
imidazol
util
rout
previous
employ
group
scheme
treatment
sodium
sulfit
ethanolwat
solut
result
simultan
deacetyl
select
deiodin
provid
key
intermedi
acetyl
gener
protect
intermedi
need
prodrug
synthesi
parallel
organometal
coupl
reagent
synthes
start
commerci
avail
still
coupl
gave
altern
use
acetyl
still
coupl
provid
desir
doubl
prodrug
synthesi
mcguigan
protid
start
commerci
avail
lalanin
util
literatur
procedur
gener
phosphoramid
scheme
reaction
flexim
presenc
tertbutyl
magnesium
chlorid
provid
desir
mcguigan
protid
yield
success
synthesi
three
flexanalogu
compound
screen
panel
filovirus
includ
ebov
marv
sudv
well
hemorrhag
fever
virus
lassa
rift
valley
fever
first
seri
assay
util
hela
cell
infect
liveviru
isol
ebov
makona
sudv
gulu
marv
activ
three
virus
observ
mcguigan
prodrug
best
activ
sudv
tabl
second
seri
assay
util
cell
infect
recombin
report
ebov
lassa
rift
valley
fever
virus
observ
first
seri
assay
compound
activ
ebov
similar
concentr
howev
compound
tabl
infecti
diseas
ebov
continu
pose
seriou
health
threat
due
high
mortal
rate
associ
deadli
virus
ongo
studi
identifi
variou
therapeut
potenti
ebov
treatment
current
fda
approv
vaccin
therapeut
imper
effect
treatment
option
develop
within
studi
found
compound
exhibit
antivir
activ
recombin
report
ebov
cell
though
surprisingli
mcguigan
prodrug
less
potent
ec
lm
lm
respect
wildtyp
virus
hela
cell
compound
detect
activ
though
compound
inhibit
ebov
sudv
ec
lm
respect
differ
activ
cell
compar
hela
cell
like
due
differ
specif
metabol
compound
cell
line
howev
studi
need
confirm
hypothesi
effort
current
underway
better
understand
mechan
action
compound
might
interact
viral
rdrp
viral
replic
enzym
result
studi
report
becom
avail
